Table S1 Clinicopathological characterization in HCC patients from TCGA database

Characteristics	DPH1 expression, n (%)			DPH2 expression, n (%)			DPH3 expression, n (%)			DPH5 expression, n (%)			DPH6 expression, n (%)			DPH7 expression, n (%)		
	Low (N=185)	High (N=186)	P value	Low (N=185)	High (N=186)	P value	Low (N=185)	High (N=186)	P value	Low (N=185)	High (N=186)	P value	Low (N=185)	High (N=186)	P value	Low (N=185)	High (N=186)	P value
Pathologic N stage (N=256)			0.560			0.637			1			0.16			1			0.717
N0	132 (51.6)	120 (46.9)		125 (48.8)	127 (49.6)		118 (46.1)	134 (52.3)		121 (47.3)	131 (51.2)		115 (44.9)	137 (53.5)		118 (46.1)	134 (52.3)	
N1	1 (0.4)	3 (1.2)		1 (0.4)	3 (1.2)		2 (0.8)	2 (0.8)		0 (0)	4 (1.6)		2 (0.8)	2 (0.8)		1 (0.4)	3 (1.2)	
Pathologic M stage (N=270)			0.168			0.131			0.69			0.542			1			1
M0	140 (51.9)	126 (46.7)		131 (48.5)	135 (50)		127 (47)	139 (51.5)		125 (46.3)	141 (52.2)		126 (46.7)	140 (51.9)		126 (46.7)	140 (51.9)	
M1	4 (1.5)	0 (0)		4 (1.5)	0 (0)		1 (0.4)	3 (1.1)		3 (1.1)	1 (0.4)		2 (0.7)	2 (0.7)		2 (0.7)	2 (0.7)	
Pathologic stage (N=347)			0.824			0.19			0.74			0.259			<0.05			0.29
Stage I & Stage II	132 (38)	125 (36)		132 (38)	125 (36)		128 (36.9)	129 (37.2)		132 (38)	125 (36)		134 (38.6)	123 (35.4)		128 (36.9)	129 (37.2)	
Stage III & Stage IV	45 (13)	45 (13)		39 (11.2)	51 (14.7)		43 (12.4)	47 (13.5)		40 (11.5)	50 (14.4)		36 (10.4)	54 (15.6)		39 (11.2)	51 (14.7)	
Gender (N=371)			0.767			<0.01			0.713			0.417			0.417			0.16
Female	59 (15.9)	62 (16.7)		75 (20.2)	46 (12.4)		62 (16.7)	59 (15.9)		64 (17.3)	57 (15.4)		64 (17.3)	57 (15.4)		54 (14.6)	67 (18.1)	
Male	126 (34)	124 (33.4)		110 (29.6)	140 (37.7)		123 (33.2)	127 (34.2)		121 (32.6)	129 (34.8)		121 (32.6)	129 (34.8)		131 (35.3)	119 (32.1)	
Age (N=370)			0.603			0.349			0.296			0.349			0.349			<0.05
≤60 years	91 (24.6)	86 (23.2)		93 (25.1)	84 (22.7)		83 (22.4)	94 (25.4)		84 (22.7)	93 (25.1)		84 (22.7)	93 (25.1)		77 (20.8)	100 (27)	
>60 years	94 (25.4)	99 (26.8)		92 (24.9)	101 (27.3)		101 (27.3)	92 (24.9)		101 (27.3)	92 (24.9)		101 (27.3)	92 (24.9)		108 (29.2)	85 (23)	
Height (N=339)			0.334			0.994			0.124			0.403			0.761			<0.01
<170 cm	103 (30.4)	96 (28.3)		101 (29.8)	98 (28.9)		94 (27.7)	105 (31)		103 (30.4)	96 (28.3)		99 (29.2)	100 (29.5)		86 (25.4)	113 (33.3)	
≥170 cm	65 (19.2)	75 (22.1)		71 (20.9)	69 (20.4)		78 (23)	62 (18.3)		66 (19.5)	74 (21.8)		72 (21.2)	68 (20.1)		81 (23.9)	59 (17.4)	
BMI (N=335)			0.471			0.135			0.139			0.787			0.055			<0.05
≤25 kg/m^2	91 (27.2)	86 (25.7)		83 (24.8)	94 (28.1)		82 (24.5)	95 (28.4)		90 (26.9)	87 (26)		80 (23.9)	97 (29)		77 (23)	100 (29.9)	
>25 kg/m^2	75 (22.4)	83 (24.8)		87 (26)	71 (21.2)		86 (25.7)	72 (21.5)		78 (23.3)	80 (23.9)		88 (26.3)	70 (20.9)		88 (26.3)	70 (20.9)	
Prothrombin time (N=294)			0.154			0.344			0.84			0.43			<0.01			0.78
≤4 s	110 (37.4)	96 (32.7)		107 (36.4)	99 (33.7)		108 (36.7)	98 (33.3)		102 (34.7)	104 (35.4)		93 (31.6)	113 (38.4)		109 (37.1)	97 (33)	
>4 s	39 (13.3)	49 (16.7)		51 (17.3)	37 (12.6)		45 (15.3)	43 (14.6)		48 (16.3)	40 (13.6)		55 (18.7)	33 (11.2)		45 (15.3)	43 (14.6)	
Vascular invasion (N=315)			0.767			0.173			0.699			<0.05			0.234			<0.05
No	106 (33.7)	100 (31.7)		113 (35.9)	93 (29.5)		103 (32.7)	103 (32.7)		113 (35.9)	93 (29.5)		109 (34.6)	97 (30.8)		113 (35.9)	93 (29.5)	
Yes	58 (18.4)	51 (16.2)		51 (16.2)	58 (18.4)		57 (18.1)	52 (16.5)		45 (14.3)	64 (20.3)		50 (15.9)	59 (18.7)		45 (14.3)	64 (20.3)	

HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; BMI, body mass index.